Conjugal Multiple Sclerosis: Population-Based Prevalence and Recurrence Risks in Offspring
Ann Neurol 48:927-931, Evers,G.C.,et al, 2000
Offspring Recurrence Rates and Clinical Characteristics of Conjugal Multiple Sclerosis
Lancet 349:1587-1590, Robertson,N.P.,et al, 1997
Clinical and Subclinical Neurological Involvement in Children of Conjugal Multiple Sclerosis Patients
Multiple Sclerosis 1:170-172, Constantinescu,C.S.,et al, 1996
Conjugal Multiple Sclerosis:Immunogenetic Characterization and Analysis of T-and B-Cell Reactivity to Myelin Proteins
Neurol 42:577-582, Frederickson,S.,et al, 1992
Conjugal Multiple Sclerosis:A Clinical and Laboratory Study
Neurol 41:1320-1321, Finelli,P.F., 1991
Conjugal Multiple Sclerosis
In Handbook of Clinical Neurol, Elsivier Publ, Amsterdam 47:291985., Myrianthopoulos,N.C., 1985
Familial and Conjugal Multiple Sclerosis
Brain 86:315-332, Schapira,K.,et al, 1963
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
A 40-Year-Old Woman Presenting with Encepatholopathy and Paraparesis
Neurol 101:e94-e98, AlSabah,A.,et al, 2023
Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis
Neurol 100:47-48, Murphy,O.C. et al, 2023
Differentiating Multiple Sclerosis from AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease with Imaging
Neurol 100:e308-e323, Cortesa,R.,et al, 2023
Endovascular vs Medical Management for Late Anterior Large Vessel Occlusion With Prestroke Disability
Neurol 100:e751-e763, Siegler, J.E., et al, 2023
Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder
Neurol 100:e1418-e1432, Cacciaguerra, L.,et al, 2023
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Clinicopathologic Conference, Granulomatosis with Polyangiitis
NEJM 387:1022-1032, Case 28-2022, 2022
A New Case of Neuromyelitis Optica Spectrum Disorders with Unknown Fever and Subacute Cognitive Decline with Normal Images
Cureus 14:e24950, Furuya,K. & Itoh,M., 2022
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Intracerebral Hemorrhage in Patients with Neuromyelitis Optica:Case Report with Literature Review for Possible Pathological Association
Case Rep Neurol 13:157-165, Elshony,H.S.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Acute Flaccid Myelitis: Cause, Diagnosis, and Management
Lancet 394:334-397, Murphy, O.C.,et al, 2021
Adults with Cerebral Palsy Require Ongoing Neurologic Care
Ann Neurol 89:860-871, Smith, S.E.,et al, 2021
Pregnancy in Patients with AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
Neurol 96:e2006-e2015, Collongues, N.,et al, 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Sequential Bilateral Vision Loss in a Woman with Scalp Tenderness and Jaw Claudication
JAMA Neurol 78:878-879, Kaufman, A.R.,et al, 2021
Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis
Neurol 97:e414-e422, Jolliffe, E.A.,et al, 2021
Bornavirus Encephalitis Shows a Characteristic Magnetic Resonance Phenotype in Humans
Ann Neurol 88:723-735, Finck, T.,et al, 2020
Comorbidity is Associated with Disease Activity in MS
Neurol 95:e446-e456, Salter, A.,et al, 2020
A 10-Year-Old Girl with Muscle Stiffness
Neurol 95:e773-e778, Prior, D.E. & Ghosh, P.S., 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Radiologically Isolated Syndrome: A Review for Neuroradiologists
AJNR 41:1542-1549, Hosseiny, M.,et al, 2020
A Patient with a History of Weight Loss Presenting with Seizures
Neurol 95:e2038-e2042, Tang, G. & Benavides, D.R., 2020
Bilateral Middle Cerebellar Peduncle Lesions:Neuroimaging Features and Differential Diagnoses
Brain Behav 10:e01778, Jiang,J.,et al, 2020
Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Melbourne Mobile Stroke Unit and Reperfusion Therapy
Stroke 51:922-930, Zhao, H.,et al, 2020
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
Clinical Characteristics, Risk Factors, and Outcomes of POEMS Syndrome
Neurol 95:e268-e279, Keddie, S.,et al, 2020
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis
JAMA Neurol 76:1446-1456, Sinnecker, T.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled Trial
Lancet 394:1713-1723,1687, The CRASH-3 trial collaborators, 2019
Long-Term Treatment Effect in Cerebrotendinous Xanthomatosis Depends on Age at Treatment Start
Neurol 92:e83-e95, Stelten, B.M.L.,et al, 2019
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019